Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AP09004 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Early patients | EXPERIMENTAL | - |
| Moderate Patients | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AP09004 | DRUG | - |
| Carbidopa/Levodopa, immediate release | DRUG | - |
* Subjects between the ages of 18 and 75 years of age inclusive; * For early patients only: Subject with Parkinson's disease with a stable response to Levodopa (not suffering from "wearing off") and currently treated with IR-Carbidopa/Levodopa containing 300-500mg Levodopa per day up to 4 doses per ...
Top 20 of 22 competitors
AP09004 is an investigational small molecule being developed for the treatment of Parkinson's Disease. It is currently in Phase 2 clinical development, with one completed trial evaluating its pharmacokinetics and pharmacodynamics in patients with the condition.
AP09004 is being developed by Indaptus Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol INDP. The company is conducting clinical research on this investigational drug for Parkinson's Disease.
AP09004 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for Parkinson's Disease.
AP09004 has one completed clinical trial, registered as NCT00918177, titled "An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease." This Phase 2 study enrolled 72 participants in Israel.
AP09004 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Parkinson's Disease. The drug has completed one clinical trial, but it has not yet received regulatory approval for any indication.
The specific molecular target or mechanism of action for AP09004 has not been disclosed in available clinical trial information. The drug is being studied as a small molecule for Parkinson's Disease, but its precise biological pathway is not publicly detailed.